massively parallel sequencing
Illumina, GenoScreen Partner to Comarket Genomic Testing for Multidrug-Resistant TB
The firms will comarket Illumina next-generation sequencing reagents with GenoScreen's Deeplex Myc-TB NGS-based test for antibiotic resistance in TB.
Thermo Fisher Scientific Receives CE-IVD Mark for NGS Aneuploidy Diagnostic Software Workflows
The CE-IVD Mark covers two NGS-based diagnostic workflows: low-pass whole-genome aneuploidy Dx w1.0 and low-pass whole-genome aneuploidy Mosaic Dx 1.0.
California, Other States to Cover Rapid WGS of Newborns Under Medicaid, but Questions of Access Loom
Premium
Though the funding is technically there, doctors may not be comfortable ordering the test and hospitals may wonder if they'll lose money from it.
NGeneBio Receives CE-IVD Mark for NGS-Based Cancer Panel
The firm's accompanying software analyzes companion diagnostic biomarkers such as EGFR, BRAF, KRAS, HER2, and ROS1 genes.
European Union to Review Illumina's Planned Grail Acquisition Under New Guidance
Illumina reaffirmed its commitment to the $8 billion deal and said it does not believe the European authorities have jurisdiction to review it.
Mar 30, 2021
FTC Moves to Block Illumina's $8B Grail Acquisition
Feb 25, 2021
Feb 24, 2021
Adaptive Biotechnologies Q4 Revenues Rise 25 Percent
Nov 10, 2020